SYNLOGIC
Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. The company's lead programs target patients with rare genetic metabolic diseases, including phenylketonuria and secondary hyperoxaluria. Synlogic is also hard at work on synthetic biotics to address more prevalent conditions, including inflammatory bowel disease, cancer, and other metabolic conditions.
SYNLOGIC
Industry:
Biotechnology Health Care Therapeutics
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.synlogictx.com
Total Employee:
51+
Status:
Active
Contact:
(617)401-9975
Email Addresses:
[email protected]
Total Funding:
472.42 M USD
Technology used in webpage:
IPv6 Akamai Hosted
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Q32 Bio
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Translate Bio
Translate Bio is a biotechnology company that specializes in biotechnology, RNA therapeutics, and rare diseases.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Ginkgo Bioworks
Ginkgo Bioworks investment in Post-IPO Equity - Synlogic
Rock Springs Capital
Rock Springs Capital investment in Series C - Synlogic
Arctic Aurora LifeScience
Arctic Aurora LifeScience investment in Series C - Synlogic
New Enterprise Associates
New Enterprise Associates investment in Series C - Synlogic
Atlas Venture
Atlas Venture investment in Series C - Synlogic
Perceptive Advisors
Perceptive Advisors investment in Series C - Synlogic
Deerfield
Deerfield investment in Series C - Synlogic
Daphne Teo
Daphne Teo investment in Series C - Synlogic
Ally Bridge Group
Ally Bridge Group investment in Series C - Synlogic
OrbiMed
OrbiMed investment in Series C - Synlogic
Key Employee Changes
Official Site Inspections
http://www.synlogictx.com Semrush global rank: 9.56 M Semrush visits lastest month: 359
- Host name: 169.180.154.104.bc.googleusercontent.com
- IP address: 104.154.180.169
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Synlogic"
OUR PEOPLE - Synlogic Therapeutics
Founded in 2014 by two of the world’s foremost experts in synthetic biology, James Collins, PhD, and Tim Lu, MD, PhD, of the Massachusetts Institute of Technology, Synlogic is comprised of visionary scientists – pioneering …See details»
Company Overview - Synlogic
For more information, please visit www.synlogictx.com or follow us on Twitter, Facebook, Instagram, and YouTube. Corporate Documents Synlogic Corporate Overview, January 2024 …See details»
Synlogic Provides Corporate Update and Outlook for 2024 - Synlogic
Jan 4, 2024 For more information, please visit https://www.synlogictx.com or follow us on Twitter, LinkedIn, Facebook, Instagram, and YouTube. Forward Looking Statements This …See details»
Synlogic - Crunchbase Company Profile & Funding
Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases. View contacts for Synlogic to access new leads and connect with decision-makers.See details»
Synlogic Provides Corporate Update and Outlook for 2024
Jan 4, 2024 - Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 …See details»
Synlogic Announces Closing of $21.0 Million Underwritten Public ...
Oct 3, 2023 Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of …See details»
News Releases | Investor Relations - Synlogic
The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts.See details»
Synlogic Announces International Nonproprietary Name Selection …
Jun 28, 2023 The World Health Organization has approved “labafenogene marselecobac”Name attributes recognize Synlogic’s proprietary technology and commitment to phenylketonuria …See details»
Synlogic Achieves Research Milestone and Earns $2.5 Million …
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed …See details»
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal
May 6, 2023 Registrational study designed to support BLA submission of first-in-class biotherapeutic. Company further streamlining organization to focus resources on execution of …See details»
Synlogic Provides Corporate Update and Outlook for 2024
Jan 4, 2024 - Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of ...See details»
Synlogic Reports First Quarter 2019 Financial Results and Provides ...
Dr. Plevy has responsibility for Synlogic’s research organization. He most recently served as Vice President, Gastroenterology Disease Area Leader and IL-23 Pathway Leader at Janssen …See details»
Brand - Synlogic Therapeutics
Brendan joined Synlogic in 2021 as Vice President, Head of Legal. Prior to joining Synlogic, he was Vice President, Legal, and member of the leadership team at Ohana Biosciences and was …See details»
Synlogic, Inc. (SYBX) Stock Price, Quote & News - Stock Analysis
Nov 22, 2024 Website https://www.synlogictx.com. Full Company Profile. Financial Performance. In 2023, Synlogic's revenue was $3.37 million, an increase of 185.68% …See details»
Synlogic Reports Third Quarter 2020 Financial Results and Provides ...
Sep 30, 2020 CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to …See details»
Designing Synthetic Biotics - Synlogic Therapeutics
Synlogic combines expertise in molecular biology, microbial engineering and physiology with innovative tools and components, including our proprietary library of synthetic biology …See details»
The History of Synthetic Biology - Synlogic Therapeutics
Brendan joined Synlogic in 2021 as Vice President, Head of Legal. Prior to joining Synlogic, he was Vice President, Legal, and member of the leadership team at Ohana Biosciences and was …See details»
Synlogic Announces Promotion of Antoine 'Tony' Awad to Chief …
CAMBRIDGE, Mass., July 30, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today …See details»
Synlogic Enters Research Collaboration with Roche for …
CAMBRIDGE, Mass., June 17, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, …See details»